Nicholas Bevins, MD, PhD, discusses the results from an in silico comparison of frequently used next-generation sequencing panels. The analysis aimed to identify the impact of the panel composition on tumor mutational burden calculations. Results from the analysis were presented in a poster at the 2019 Association for Molecular Pathology Annual Meeting and Expo.
Nicholas Bevins, MD, PhD, a postgraduate resident at the University of California, San Diego, discusses the results from an in silico comparison of frequently used next-generation sequencing panels. The analysis aimed to identify the impact of the panel composition on tumor mutational burden (TMB) calculations. Results from the analysis were presented in a poster at the 2019 Association for Molecular Pathology (AMP) Annual Meeting and Expo.
Clinicians at the University of California, San Diego, questioned what the difference was between different lab-based panels and Foundation Medicine panels, so investigators sought to compare how the different panel compositions may impact TMB.
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More